➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Cenderitide

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Cenderitide?

Cenderitide is an investigational drug.

There have been 5 clinical trials for Cenderitide. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Heart Failure, Renal Insufficiency, and Myocardial Infarction. The leading clinical trial sponsors are Capricor Inc., Mayo Clinic, and Integrium.

There are two US patents protecting this investigational drug and two hundred and seventy-seven international patents.

Recent Clinical Trials for Cenderitide
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device SupportMayo ClinicPhase 1
Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal ImpairmentCapricor Inc.Phase 1/Phase 2
Safety Study of Cenderitide in Stable Chronic Heart FailureCapricor Inc.Phase 2

See all Cenderitide clinical trials

Clinical Trial Summary for Cenderitide

Top disease conditions for Cenderitide
Top clinical trial sponsors for Cenderitide

See all Cenderitide clinical trials

US Patents for Cenderitide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cenderitide   Start Trial Methods of treatment of heart failure with natriuretic peptides Capricor Therapeutics, INC. (Beverly Hills, CA)   Start Trial
Cenderitide   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cenderitide

Drugname Country Document Number Estimated Expiration Related US Patent
Cenderitide European Patent Office 2632477 2030-10-29   Start Trial
Cenderitide World Intellectual Property Organization (WIPO) 2012058585 2030-10-29   Start Trial
Cenderitide Australia 2012328780 2031-10-25   Start Trial
Cenderitide Australia 2013226031 2031-10-25   Start Trial
Cenderitide Australia 2013226034 2031-10-25   Start Trial
Cenderitide Australia 2013271436 2031-10-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.